Patent 12071485 was granted and assigned to Avidity Biosciences on August, 2024 by the United States Patent and Trademark Office.
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).